Skip to content

Rechercher des études

Résultats de recherche

The SYNAPSE trial is designed to study the effects of an individualized home-based cognitive training program on cognitive functions in heart-failure patients.

Conditions:
Heart Failure
Emplacement:
  • Centre de recherche du centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada
  • Preventive medicine and physical activity center (centre EPIC), Montreal heart Institute, Montréal, Quebec, Canada
Sexe:
ALL
Âges:
Over 50

EMMA-Can is an open-label randomized control trial comparing the recurrence risk in patients with chronic subdural hematoma (CSDH) undergoing standard of care treatment (surgical drainage and/or medical management) with or without embolization of the middle meningeal (EMMA).

Conditions:
Chronic Subdural Hematoma
Emplacement:
  • University of Manitoba, Winnipeg, Manitoba, Canada
Sexe:
ALL
Âges:
Over 18

Twenty people with hearing impairment will be tested and fitted binaurally with hearing aids. During a real-world listening situation, each participant will be asked to compare one program with a novel algorithm to one with a standard microphone configuration. They will provide ratings on a range of outcome measures including overall preference and awareness of background noise. Overall and specific preferences for the different programs/algorithms will be determined by their subjective responses to determine if there is a significant difference between the two programs.

Conditions:
Hearing Loss
Emplacement:
  • Western University, London, Ontario, Canada
Sexe:
ALL
Âges:
18 - 99

The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio VT Cryoablation System in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT)

Conditions:
Sustained VT
Emplacement:
  • Montreal Heart Institute, Montreal, Quebec, Canada
  • McGill University, Montreal, Quebec, Canada
Sexe:
ALL
Âges:
Over 18

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Conditions:
Lung Adenocarcinoma | Ovarian Cancer
Emplacement:
  • Research Site, Edmonton, Alberta, Canada
  • Research Site, Montréal, Quebec, Canada
  • Research Site, Montreal, Quebec, Canada
  • Research Site, London, Ontario, Canada
  • Research Site, Toronto, Ontario, Canada
Sexe:
ALL
Âges:
18 - 130

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Conditions:
Prostate Cancer | Biliary Cancer | Gastric Cancer | Colorectal Cancer | Bladder Cancer | Non-small Cell Lung...
Emplacement:
  • Research Site, London, Ontario, Canada
  • Research Site, Montreal, Quebec, Canada
  • Research Site, Vancouver, British Columbia, Canada
  • Research Site, Toronto, Ontario, Canada
  • Research Site, Ottawa, Ontario, Canada
  • Research Site, Montreal, Quebec, Canada
  • Research Site, Kelowna, British Columbia, Canada
  • Research Site, Toronto, Ontario, Canada
Sexe:
ALL
Âges:
18 - 130

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.

Conditions:
Metastatic Non-small Cell Lung Cancer | Advanced Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations
Emplacement:
  • ArriVent Investigative Site, Toronto, Ontario, Canada
  • ArriVent Investigative Site, Edmonton, Alberta, Canada
Sexe:
ALL
Âges:
Over 18

Cancer and its treatments often result in severe toxicities and side effects that, over the course of treatment, results in weight loss and depletion of key nutrients. Loss of muscle mass and strength during cancer treatment is a critical problem because it negatively affects patient response and tolerance to therapy and post-treatment recovery. To restore the nutritional status, it is imperative to stimulate muscle protein anabolism. Eggs are high quality protein source, popular and well tolerated by cancer patients. Therefore, the objective of this study is to determine whether a nutritional intervention of ≥2 eggs can aid in restoring nutritional status and improving immune function and quality of life of cancer patients' post-treatment. It is an 8- week randomised clinical trial with parallel arm assignment. Half of the participants will receive the nutritional intervention (Early Intervention) and the other half will be on standard of care or usual diet for first 4 weeks. Starting from week 5, all participants will receive the nutrition intervention till week 8 (Delayed Intervention). Dietary intake (foods and nutrients), cumulative protein intake (g protein/kg body weight), immunological measures, physical performance and quality of life has been planned to be assessed over time and between groups to evaluate the feasibility of an egg intervention in meeting recommended protein intakes for patients with cancer.

Conditions:
Cancer | Other Malnutrition
Emplacement:
  • University of Alberta, Edmonton, Alberta, Canada
Sexe:
ALL
Âges:
Over 18

The efficacy of treatment with metformin for promoting cognitive recovery and brain growth in children/adolescents treated for medulloblastoma will be investigated in a multi-site Phase III randomized double-blind placebo-controlled parallel arm superiority trial. Specifically, in children/adolescents aged 7 years to 17 years and 11 months who have completed treatment for medulloblastoma, is oral administration of metformin for 16 weeks associated with greater improvement of cognitive function and brain growth compared to placebo administered for 16 weeks?

Conditions:
Cognitive Impairment | Medulloblastoma, Childhood
Emplacement:
  • Children's & Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada
  • Children's Hospital, London Health Sciences Centre, London, Ontario, Canada
  • Montreal Children's Hospital, Montréal, Quebec, Canada
  • Stollery Children's Hospital, Edmonton, Alberta, Canada
  • Hamilton Health Sciences - McMaster Children's Hospital, Hamilton, Ontario, Canada
  • CHU Sainte-Justine, Montréal, Quebec, Canada
  • Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada
  • Cancer Care Manitoba, Winnipeg, Manitoba, Canada
  • Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
  • CHU de Québec - Université Laval, Quebec City, Quebec, Canada
  • Alberta Children's Hospital, Calgary, Alberta, Canada
  • Izaak Walton Killam (IWK) Health Centre, Halifax, Nova Scotia, Canada
  • The Hospital for Sick Children, Toronto, Ontario, Canada
  • CHU de Sherbrooke, Sherbrooke, Quebec, Canada
Sexe:
ALL
Âges:
7 - 21

Following Ethics approval, all adult patients undergoing surgery to fix the wrist fracture will be approached and consent to undergo this study. The amount of waste generated from general anesthetic, regional anesthetic and regional+general anesthetic will be collected and weighed. Patients undergoing this type of wrist surgery have only regional anesthetic, or general anesthetic, or both ie. regional anesthetic and general anesthetic. The aim of the study is to compare the amount of waste generated from each type of anesthetic and this will give us a better idea of which anesthetic is more environmentally sustainable.

Conditions:
Carbon Footprint in Anesthetic
Emplacement:
  • Sturgeon Community Hospital, St. Albert, Alberta, Canada
  • University of Alberta Hospital, Edmonton, Alberta, Canada
Sexe:
ALL
Âges:
Over 19